[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Article
November 2004

Auditory Effects After Organ Preservation Protocol for Laryngeal/Hypopharyngeal Carcinomas

Arch Otolaryngol Head Neck Surg. 2004;130(11):1265-1268. doi:10.1001/archotol.130.11.1265

Objective  To investigate the prevalence of hearing loss after concomitant radiochemotherapy in patients enrolled in a larynx preservation protocol.

Design  Prospective study.

Setting  Consecutive patients treated in a tertiary cancer center hospital between 2001 and 2002.

Patients  Eligible subjects included patients prospectively enrolled in an organ preservation protocol based on concomitant radiotherapy and chemotherapy (cisplatin and paclitaxel).

Main Outcome Measures  Descriptive analysis of the results of audiologic evaluations, including pure-tone audiometry and immitance audiometry, which were performed prior to and 8 months after treatment. Change in hearing sensitivity was computed relative to baseline measures. Criteria to indicate hearing decrease after the treatment were defined as either a 20-dB decrease at any single test frequency or a 10-dB decrease at any 2 adjacent test frequencies.

Results  A total of 11 patients were analyzed. Four patients (36%) had hearing loss after the treatment.

Conclusion  Our results suggest that the prevalence of hearing loss after radiochemotherapy in larynx preservation protocols is high (36%); however, it was usually mild and asymptomatic.